INTERCEPT goes beyond to protect patients*, improve availability, and deliver value.
Protect Patients*
Improve Availability
Deliver Value
INTERCEPT® Blood System for Platelets
PATHOGEN REDUCTION SYSTEM
Pathogen Reduced Cryoprecipitated Fibrinogen Complex
INTERCEPT® Fibrinogen Complex (IFC)
INTERCEPT® Blood System for Plasma
PATHOGEN REDUCTION SYSTEM
Pathogen Reduced Plasma, Cryoprecipitate Reduced (PRPCR)
Why Blood Matters, Cal Miller’s Story
Listen as Dash Miller tells his brother Cal’s story, sharing the impact that the INTERCEPT Blood System had in delivering safe blood products in Cal’s time of need.
Benefits of IFC:
Blood Center & Blood Bank Perspectives
What's New
In this webinar, Dr. Patricia Kopko, Director of Transfusion Medicine at the University of California, San Diego, and Austin Dyches, Director of Biologics Manufacturing at OneBlood, share their institutions’ experience with IFC. They discuss how IFC benefits blood center production, improves hospital efficiencies (shortening turnaround times and minimizing wastage), and impacts patient care with immediate availability† due to its 5-day post thaw shelf life, improving patient access to fibrinogen supplementation during hemorrhage at their institutions.
Treating Coagulopathy: How to be Ready When Minutes Matter
What's New
Timely administration of fibrinogen and other key clotting factors is essential to treating coagulopathy associated with fibrinogen deficiency. Access to fibrinogen sources (such as cryo AHF and fibrinogen concentrates) can be challenging given their long wait times, need to reconstitute, cost, wastage and short shelf life. Join us to learn how INTERCEPT® Fibrinogen Complex (IFC) is immediately available† due to its 5-day post thaw shelf life, improving patient access to fibrinogen supplementation during hemorrhage. Hear experts in OB, CV & trauma anesthesia speak to their IFC experiences and how it impacts their patient care.
Resources
Learn More
Find out more about the INTERCEPT Blood System.
*There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. For a full list of pathogens, please refer to package inserts. †INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when stored thawed; and when stored frozen requires thawing prior to use.
- The INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation.
- INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex Package Insert.
- INTERCEPT Blood System for Plasma Package Insert, Cerus Corporation.
- INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Plasma, Cryoprecipitate Reduced Package Insert, Cerus Corporation.
- Collier, T. and Chrebtow , V. “Impact of Pathogen Reduction (PR) vs. LVDS Testing on Platelet Availability: A Study Based on Real-World Experience.” AABB 2022. Poster P-IV-8.
- Prichard, A.B., et al. “Comparing Usable Shelf-Life of Pathogen Reduced Platelets vs. LVDS Screened Platelets”. AABB 2022. Poster P-IV-2.
- Meyer DE, et al. The Journal of Trauma and Acute Care Surgery 2017;83:19-24.
- Harm SK, et al. Transfusion. 2018 Apr; 58(4):938-942.
- Ruby KN, et al. Transfusion. 2018 Jul; 58(7):1665-1669.
- Cerus Corporation. (2022) “Assessing Impact of INTERCEPT Fibrinogen Complex (IFC) on Wastage and Massive Transfusion Protocols (MTPs)”. [Case Study].